Eleven percent of activated clinical trial sites enroll exactly zero patients. That figure, from Tufts Center for the Study of Drug Development, sits alongside a finding that 37 percent of sites enroll fewer participants than planned, and together they explain why first patient in (FPI) dates slip so reliably, and so expensively, for sponsors who treated site activation as the hard part.

The real chokepoint is earlier. WCG’s 2026 Clinical Research Site Challenges Report found that more than half of sites spent at least three months on study start-up, with 13 percent reporting a process that stretched beyond five months. Budget development and negotiation was the single largest contributor to that drag, cited by 56 percent of sites. The protocol complexity running underneath all of it has grown steadily: since 2015, Tufts CSDD data show Phase III trials now require 42 percent more procedures and carry 37 percent more endpoints than they did a decade ago, which lengthens every downstream negotiation and IRB submission that touches the protocol.

Two levers cut more time than any other. Sites that resolve budget and contract terms early, using industry-leading negotiation best practices, can reduce budget and contract timelines by up to 40 to 60 percent, according to WCG’s analysis. And recruitment planning that runs in parallel with site activation, rather than waiting for a green light, means enrollment can begin the moment a site opens. Neither approach is complicated, but both require sponsors to treat start-up as an integrated sequence rather than a checklist of handoffs. Site selection feeds budget accuracy, budget accuracy feeds contract speed, and contract speed feeds the moment an investigator can actually consent a patient.

The data-driven site identification piece matters more than it once did. WCG’s ClinSphere Trial IntelX platform,, is designed to surface which sites have actually enrolled comparable patients in comparable protocols, not just which sites submitted a feasibility survey saying they could. A site that looks eligible but lacks the patient population or investigator bandwidth costs more in activation resources than it ever contributes in enrollment, and that cost shows up directly in how far past the FPI date a trial drifts. The number to watch is the share of activated sites that enroll at least one patient: if it stays near that figure, start-up improvements may not be reaching the sites that matter most.

Source link: https://www.wcgclinical.com/insights/first-patient-in-clinical-trials/

Website | + posts

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.